This is exemplified by the reduced responsiveness of patients with mutations in autophagy-related genes, such as autophagy-related 2B (ATG2B), to BCG immunotherapy for bladder cancer [76]. The gene discussed is ATG2B; the disease is urinary bladder carcinoma.